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A B S T R A C T
We evaluated the effectiveness of latanoprost (Xalatan™) monotherapy in primary open angle glaucoma (POAG).
Latanoprost is a prostaglandin analogue, the pure 15(R) epimer of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2-
-isopropyl ester. As a prodrug it is being activated by enzymatic hydrolysis in the cornea after which it becomes active
acid of latanoprost. Latanoprost is lowering the intraocular pressure (IOP) by increasing the uveoscleral outflow. In
this study, latanoprost was used once daily as monotherapy what offers much better compliance for the patients than
other combinations of drugs, preserving good IOP control. Based on the significant reduction of the IOP, measured on
the day 60 of the trial (mean change in IOP was –5.1 mmHg, with 95% confidence interval in range from –5.6 to –4.5),
it is concluded that use of latanoprost is advisable when calculating better IOP control, few side-effects and reductions
in costs of potential surgical procedures.
Key words: latanoprost, Xalatan™, monotherapy, glaucoma, treatment, effectiveness
Introduction
A glaucoma is the disease characterised in most of
the cases by elevated intraocular pressure (IOP) above
21 mm Hg, visual field loss and optic nerve head (ONH)
changes1–4. In normotensive glaucoma IOP is considered
to be »normal« (less than 21 mm Hg). Medicamentous
treatment of glaucoma patients has very much changed
in the past few years due to appearance.
Latanoprost, i.e., Xalatan™ (Pharmacia & Upjohn;
Pfizer group, USA) is a prostaglandin analogue, the
pure 15(R) epimer of 13,14-dihydro-17-phenyl-18,19,20-
-trinor-PGF2-isopropyl ester. As a prodrug it is being
activated by enzymatic hydrolysis in the cornea after
which it becomes active acid of latanoprost. Latanoprost
is found to be lowering the IOP by increasing the uve-
oscleral outflow1,3,5–7, whereby other locally applied me-
dications reduce IOP either by increasing the outflow of
fluid through the trabecular drainage system or by re-
ducing the production of fluid in the eye8. It is being
given once daily in a 0.005 % concentration predomi-
nantly in primary open angle glaucoma (POAG), ocular
hypertension (OH) and normotensive glaucoma (NTG),
but can be used also in other glaucoma types1,5,9. As a
monotherapy latanoprost lowers IOP by 6–8 mm Hg af-
ter 6 months application whereby IOP falls mostly dur-
ing first 2 weeks and remains stabile in the next pe-
riod1,5,10–12. Latanoprost can be successfully used as the
additive therapy of glaucoma patients receiving already
maximum tolerated therapy8, it lowers diurnal varia-
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tions of IOP14,15 and has been recently accepted as a
first-line therapy for some glaucoma types.
The objective of this investigation is to determine
whether and in what level latanoprost eye-drops as a
monotherapy can substitute single and combined therapy
of other antiglaucoma drugs in POAG.
Subjects and Methods
Total number of the patients in the study was 159
(males/females = 72/87). The first group of the patients
with glaucoma consisted of 16 newly discovered patients
with previously untreated disease (males/females = 5/11).
The second group of the patients (67 men and 76
women), had a glaucoma for the longer period of time. In
this group the median of the disease was 4 years, 3
years for males and 5 years for femals (Mann-Whitney
U test, p>0.05, Table 1).
All patients that participated in the trial had both
eyes affected with the same type of glaucoma (POAG).
Patients were treated during the 60 days by 0.005%
latanoprost monotherapy with one drop per eye daily,
applied in the evening. Intraocular pressure was mea-
sured by the Goldmann aplanation tonometry. IOP of
both eyes was measured and mean of the both values
was taken into consideration for the statistics. IOP was
measured in both groups of glaucoma patients on three
time points: day 0 (initiation of the therapy), day 15 and
day 60 (end of the trial). In the group of the patients who
had a previous therapy there was no wash out period.
Their earlier therapy, presented in Table 2, was changed
because of the unsatisfying effectiveness, in several
cases combined with poor compliance, local or systemic
side effects or poor cooperation of the patient using mul-
tiple therapy. The IOP criteria for the change to lata-
noprost monotherapy were the values of  22 mmHg.
During the investigation the principles emphasized
in the Helsinki Declaration were followed and an in-
formed consent was obtained from the subjects.
Statistical analysis was made using Mann-Whitney
U test for comparison of independent groups, and Wil-
coxon matched pairs test for change in IOP between
time points. 95% confidence interval (95% CI) for mean
drop in IOP was estimated as more informative parame-
ter of efficacy, in comparison to the simple mean. Fried-
man test was used to compare the IOP changes within
all time points (0, 15 days and 60 days) of the groups of:
newly discovered glaucoma patients treated with lata-
noprost, and previously treated patients that were
switched to latanoprost monotherapy. Friedman test is
a nonparametric version of the randomized design ana-
lysis of variance. It is a generalization of the Wilcoxon
test for paired samples to apply to more than two
groups. The results of the group measurements at three
time points were mutually compared by means of Steel-
-Dwass test, nonparametric version of Tukey test.
Results
Mean IOP values measured by the aplanation tono-
metry in the group of the newly discovered patients, on
the days 0, 15 and 60 are presented in Table 3. Mean
IOP values between the groups of male (24.9 mmHg)
and female patients (23.2 mmHg) did not differ, and
there were no differences in the male and female IOP at
individual time points (Table 3). However, on the day 15
(Table 4) and day 60 (Table 5) we observed significant
lowering of IOP following latanoprost monotherapy.
Table 4 shows that on the day 15 of the latanoprost
monotherapy IOP difference/drop in the newly discovered
glaucoma patients was more pronounced in the females
–6.6 (95% CI from –8.8 to –4.5) then in the males –5.9
(95% CI from –11.8 to –0.1). On the day 60 IOP differ-
ence/drop in the in the newly discovered glaucoma pa-
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TABLE 1






All patients (N  143) 4 1–36
Males (N  67)* 3 1–36
Females (N  76)* 5 1–23
*p > 0.05 Mann-Whitney U test
TABLE 2
THERAPY IN PATIENTS WITH PREVIOUSLY
TREATED GLAUCOMA
Previous therapy Number of patients
Beta blocker 91
Beta blocker + Pilocarpine 28
Beta blocker + Dorzolamide 16




VALUES OF INTRAOCULAR PRESSURE IN PATIENTS WITH
NEWLY DISCOVERED GLAUCOMA
Day (X ± SD) All patients (1) Males (2)* Females (3)*
0 23.6 ± 2.4 24.9 ± 2.6 23.2 ± 2.2
15 17.2 ± 2.5 19.0 ± 2.9 16.6 ± 2.0
60 17.0 ± 2.3 18.0 ± 2.8 16.6 ± 2.0
*p > 0.05 Mann-Whitney U Test
TABLE 4
DROP OF OF INTRAOCULAR PRESSURE VALUES IN PATIENTS
WITH NEWLY DISCOVERED GLAUCOMA TREATED WITH
LATANOPROST MONOTHERAPY (DAY 15 OF THE TRIAL)
All patients (1) Males (2) Females (3)
–6.4 mmHg
(from –8.2 to –4.6)
–5.9 mmHg
(from –11.8 to –0.1)
–6.6 mmHg
(from –8.8 to –4.5)
Wilcoxon matched pairs test; means and 95% confidence inter-
vals; p < 0.05 (groups 1 and 3); p = 0.06 (group 2)
U:\coll-antropolo\coll-antro-1-2005\Pavan.vp
17. lipanj 2005 10:23:54
Plate: 2 of 5
Color profile: Disabled
Black  150 lpi at 45 degrees
tients was more pronounced in the male patients group
–5.8 (95% CI from –6.6 to –5.0) then in the female pa-
tients group –4.4 (95% CI from –5.2 to –3.7, Table 5).
Similar results were observed in the group of pa-
tients whose earlier therapy, was changed because of
the unsatisfying effectiveness, poor compliance, local or
systemic side effects and similar reasons. Table 6 pre-
sents their IOP values on the days 0, 15 and 60 of the
trial. Mean IOP values between the groups of male (22.1
mmHg) and female patients (21.9 mmHg) did not differ,
and there were no differences in the male and female
IOP at individual time points (Table 6). However, on the
day 15 (Table 7) and day 60 (Table 8) we observed signi-
ficant lowering of IOP following latanoprost monothe-
rapy.
Table 7 shows that on the day 15 of the trial IOP dif-
ference/drop in the newly discovered glaucoma patients
was more pronounced in the males 4.9 (95% CI from
–5.7 to –4.2) then in the females –3.5 (95% CI from –4.9
to –2.1). Table 8 shows an additional drop of IOP on the
day 60 of the latanoprost monotherapy. Mean IOP drop
was –5.9 mmHg (95% CI from –6.6 to –5.0) in the male
glaucoma patients group, and –4.4 mmHg (95% CI from
–5.2 to –3.7) in the female patients.
Friedman and Steel-Dwass tests confirmed that lata-
noprost monotherapy significantly reduced IOP in new-
ly discovered (Table 9) and previously treated glaucoma
patients (Table 10) at days 15 and 60 of the trial. There
was no statistically significant differences between IOP
drop at days 15 and 60 of the latanoprost monotherapy
(Table 9–11). IOP values of the groups of newly disco-
vered and previously treated glaucoma patients showed
similar patterns, and did not differ at the time points 0,
15 and 60 (Mann-Whitney U test, p > 0.05).
No serious side effects or complications were re-
ported during the administration of latanoprost.
Discussion
The study shows that latanoprost can be used as a
monotherapy in the patients with POAG. It offers a
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TABLE 5
DROP OF OF INTRAOCULAR PRESSURE VALUES IN PATIENTS
WITH NEWLY DISCOVERED GLAUCOMA TREATED WITH
LATANOPROST MONOTHERAPY (DAY 60 OF THE TRIAL)
All patients (1) Males (2) Females (3)
–5.1 mmHg
(from –5.6 to –4.5)
–5.8 mmHg
(from –6.6 to –5.0)
–4.4 mmHg
(from –5.2 to –3.7)
p < 0.05 Wilcoxon matched pairs test (for all groups); means
and 95% confidence interval
TABLE 7
DROP OF OF INTRAOCULAR PRESSURE VALUES IN PATIENTS
WITH PREVIOUSLY TREATED GLAUCOMA FOLLOWING
LATANOPROST MONOTHERAPY (DAY 15 OF THE TRIAL)
All patients (1) Males (2) Females (3)
–4.2 mmHg
(from –5.0 to –3.3)
–4.9 mmHg
(from –5.7 to –4.2)
–3.5 mmHg
(from –4.9 to –2.1)
p < 0.05 Wilcoxon matched pairs test (for all groups); means
and 95% confidence interval
TABLE 6
VALUES OF INTRAOCULAR PRESSURE IN PATIENTS WITH
PREVIOUSLY TREATED GLAUCOMA
Day All patients (1) Males (2)* Females (3)*
0 22.0 ± 3.6 22.1 ± 3.8 21.9 ± 3.4
15 17.8 ± 4.4 17.2 ± 2.7 18.4 ± 5.7
60 16.9 ± 2.4 16.3 ± 2.3 17.5 ± 2.4
* p > 0.05 Mann-Whitney U test (for all groups)
TABLE 8
DROP OF OF INTRAOCULAR PRESSURE VALUES IN PATIENTS
WITH PREVIOUSLY TREATED GLAUCOMA FOLLOWING
LATANOPROST MONOTHERAPY (DAY 60 OF THE TRIAL)
All patients (1) Males (2) Females (3)
–5.1 mmHg
(from –5.7 to –4.5)
–5.9 mmHg
(from –6.6 to –5.0)
–4.4 mmHg
(from –5.2 to –3.7)
p  0.05 Wilcoxon matched pairs test (for all groups); means
and 95% confidence interval
TABLE 9
DIFFERENCES IN VALUES OF INTRAOCULAR PRESSURE FOR
THE GROUPS OF NEWLY DISCOVERED GLAUCOMA PATIENTS
AT DIFFERENT TIME POINTS OF LATANOPROST
MONOTHERAPY
Day* 15 60
0 4.46 (p < 0.001) 4.78 (p < 0.001)
15 0.11 (p > 0.05)
* Steel-Dwass test; Friedman test: p < 0.001
TABLE 10
DIFFERENCES IN VALUES OF INTRAOCULAR PRESSURE FOR
THE GROUPS OF PREVIOUSLY TREATED GLAUCOMA PA-
TIENTS AT DIFFERENT TIME POINTS OF LATANOPROST
MONOTHERAPY
Day* 15 60
0 9.74 (p < 0.001) 11.13 (p < 0.001)
15 1.96 (p > 0.05)
*Steel-Dwass test; Friedman test: p < 0.001
TABLE 11
PERCENTAGE OF PATIENTS WITH REDUCED IOP IN THE
GROUPS OF NEWLY DISCOVERED AND PREVIOUSLY TREATED















0 31.25% 44.76% 68.75% 55.24%
15 93.75% 91.55% 6.25% 8.45%
60 100% 97.20% 0% 2.80%
Steel-Dwass test: 0 vs.15 (p < 0.001); 0 vs. 60 (p < 0.001); 15 vs.
60 (p > 0.05)
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good IOP lowering effects in the newly discovered cases
as well as in those which were insufficiently controlled
by the other drugs. In the group of patients with newly
discovered POAG, latanoprost has significantly lowered
the IOP after first 15 days for –6.4 mmHg (95% CI –8.2
to –4.6) (Table 9). The result is comparable to the results
of other authors1,5,10–12,16. It is clearly noticeable that
latanoprost has managed to lower the IOP for minimum
of 4.6 mmHg what is still a good result having in mind
the fact that mean initial IOP was 23.6 mmHg (± 2.4).
After 60 days the mean IOP difference to the day 0 was
–5.1 mmHg (95% CI –5.6 to –4.5). This slight rise of IOP
is, however, not statistically significant when compared
to day 15 values (Table 9). Since the IOP values at day
60 are still significantly below the ones at day 0 of the
trial it can still be concluded that the IOP was under
control.
It is interesting to note that the difference between
minimum and maximum IOP at day 60 was smaller
than at day 15, suggesting the IOP becoming more sta-
ble and presumably with less diurnal variations. This is
important having in mind that the peaks of the IOP are
responsible for the optic nerve and visual field deterio-
ration. We also observed minor differences between IOP
changes of males and females, but the reason for this re-
mains unexplained at this time.
The IOP criteria for change to latanoprost mono-
therapy were the values of  22 mm Hg. This is a stan-
dard preswitch baseline value for IOP studies. To avoid
that the observed results of latanoprost monotherapy
arise from the regression to the mean effects (i.e., some
abnormal values of the first measurement) the se-
cond/repeated measurement, done at the beginning of
the trial served as a 0 starting point for statistical
comparisons17. Due to the severity of the disease the pa-
tients were switched to latanoprost treatment without
stopping medications. However, their IOP was poorly
controlled at that time, since there were no statistical
differences between IOP values of previously treated
and newly discovered glaucoma patients at 0 time point
of the trial (Mann-Whitney U test, p > 0.05; Results).
The reason for switching the therapy to latanoprost
was predominantly motivated by insufficient IOP con-
trol with previous medicaments. At the day 15 of the
treatment average IOP drop in the switched group was
little below the previously untreated group (where the
drug has been used as the first line medication). This
can be explained with the fact that previous therapy
must have had some small effect on IOP at this early
point of treatment. After 60 days mean IOP value has
remained almost the same as on day 15 and standard
deviation of the results is smaller, suggesting again
good activity in the average population and presumably
less diurnal variations.
The results of the group measurements at three time
points were analysed by Friedman and Steel-Dwass
tests18. The statistical analysis confirmed similar pat-
terns of IOP drop due to latanoprost monotherapy in the
groups of newly discovered and previously treated pa-
tients suffering from POAG (Table 9–11, Results). It is
worth mentioning that in both groups of patients there
were no significant differences in the efficacy of lata-
noprost monotherapy at day 15 and day 60 of the trial
(Table 9–11), which indicates that the first evaluation of
the latanoprost treatment efficacy could be done on the
basis of IOP measurements at day 0 and day 15 of the
drug administration. The finding is in agreement with
previous observation that IOP falls mostly during first 2
weeks of latanoprost monotherapy and remains stabile
in the next period1,5,10–12.
This investigation confirms data published in last
few years showing better IOP control by latanoprost
then by some other antiglaucoma medicaments1,5,16, 19.
It has also been proven that XalatanTM can be very suc-
cessfully used as an additive therapy to other medica-
tions reducing aqueous production and increasing tra-
becular outflow (e.g. beta blockers, carbonic anhydrase
inhibitors), as it’s mechanism of action is primarily in-
creasing the uveoscleral outflow1,5,20–23. Therefore it can
also be used in other glaucoma types than POAG and ocu-
lar hypertension9 but is not efficient in all24. Such re-
sults are potentially important also for the visual field
preservation due to its effect on increase of the pulsatile
blood flow25.
Latanoprost monotherapy offers much better compli-
ance for the patients than other combinations of drugs,
preserving good IOP control. It becomes even more im-
portant being aware of the reports saying that persis-
tency with latanoprost is much better comparing to
other medicaments26,27. This puts different light on the
costs of latanoprost therapy which are higher than the
ones of timolol and some other antiglaucoma medica-
ments. Despite this fact use of latanoprost is still advisab-
le when calculating better IOP control, few side-effects
and reductions in costs of potential surgical procedu-
res5,28, 29.
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EFIKASNOST MONOTERAPIJE LATANOPROSTOM (XALATANTM) U NOVOOTKRIVENIH I
PRETHODNO MEDIKAMENTOZNO TRETIRANIH BOLESNIKA S PRIMARNIM GLAUKOMOM
OTVORENOG KUTA
S A @ E T A K
U radu je ispitivana u~inkovitost monoterapije latanoprostom (Xalatan™) u primarnom glaukomu otvorenog
kuta. Latanoprost je prostagladinski analog, ~isti 15(R) epimer 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2-iso-
propyl estera. Latanoprost se aktivira enzimskom hidrolizom u ro`nici, pri ~emu postaje aktivan. Lijek sni`ava o~ni
tlak pove}avaju}i uveo-skleralno otjecanje. U studiji je utvr|ena superiornost monoterapije latanoprostom u odnosu
na druge kombinacije antiglaukomatoznih lijekova zbog zadovoljavaju}e kontrole o~nog tlaka i vrlo dobre prihvat-
ljivosti. Prosje~na redukcija intraokularnog tlaka izmjerena na kraju pra}enja (dan 60) iznosila je –5,1 mmHg u
rasponu od –5,6 do –4,5 (95% intervala pouzdanosti). Zaklju~eno je da uporaba latanoprosta omogu}uje bolju kon-
trolu intraokularnog tlaka uz manje nuzpojava i mogu}u redukciju tro{kova daljnjeg lije~enja.
J. Pavan et al.: Latanoprost Monotherapy in Glaucoma, Coll. Antropol. 29 (2005) 1: 315–319
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